Recurrent Malignant Glioma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Recurrent Malignant Glioma – Pipeline Review, H2 2016’, provides an overview of the Recurrent Malignant Glioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma

The report reviews pipeline therapeutics for Recurrent Malignant Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Recurrent Malignant Glioma therapeutics and enlists all their major and minor projects

The report assesses Recurrent Malignant Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AbbVie Inc

DNAtrix Inc

GtreeBNT Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Recurrent Malignant Glioma Overview 6

Therapeutics Development 7

Pipeline Products for Recurrent Malignant Glioma - Overview 7

Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis 8

Recurrent Malignant Glioma - Therapeutics under Development by Companies 9

Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 10

Recurrent Malignant Glioma - Pipeline Products Glance 11

Clinical Stage Products 11

Recurrent Malignant Glioma - Products under Development by Companies 12

Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes 13

Recurrent Malignant Glioma - Companies Involved in Therapeutics Development 14

2-BBB Medicines BV 14

AbbVie Inc 15

DNAtrix Inc 16

GtreeBNT Co Ltd 17

Recurrent Malignant Glioma - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

2B3-101 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Cellular Immunotherapy for Oncology - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Cellular Immunotherapy for Recurrent Malignant Glioma - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Cellular Immunotherapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Cellular Immunotherapy to Target IL-13 for Malignant Glioma - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

depatuxizumab mafodotin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

disufenton sodium - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DNX-2401 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Recurrent Malignant Glioma - Dormant Projects 42

Recurrent Malignant Glioma - Discontinued Products 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for Recurrent Malignant Glioma, H2 2016 7

Number of Products under Development for Recurrent Malignant Glioma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Recurrent Malignant Glioma – Pipeline by 2-BBB Medicines BV, H2 2016 14

Recurrent Malignant Glioma – Pipeline by AbbVie Inc, H2 2016 15

Recurrent Malignant Glioma – Pipeline by DNAtrix Inc, H2 2016 16

Recurrent Malignant Glioma – Pipeline by GtreeBNT Co Ltd, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Recurrent Malignant Glioma – Dormant Projects, H2 2016 42

Recurrent Malignant Glioma – Discontinued Products, H2 2016 43

List of Figures

List of Figures

Number of Products under Development for Recurrent Malignant Glioma, H2 2016 7

Number of Products under Development for Recurrent Malignant Glioma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Top 10 Targets, H2 2016 19

Number of Products by Stage and Top 10 Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports